IL1B and coronary artery disorder: Further, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) showed that in patients with a previous myocardial infarction concomitant with systemic inflammation, IL-1β inhibition reduced coronary disease (37).